Delighted to expand our collaboration with Biomedical Advanced Research and Development Authority (BARDA) to increase preparedness for responding to filovirus outbreaks. https://lnkd.in/eej_zkkJ
Mapp Biopharmaceutical Inc
Biotechnology Research
San Diego, California 2,750 followers
Developing monoclonal antibody drugs for unmet needs in public health and biodefense.
About us
Mapp Biopharmaceutical, Inc. is a biotechnology company located in San Diego, California, United States. Mapp's mission is to develop monoclonal antibody drugs for neglected infectious diseases. EXPANDED ACCESS POLICY Mapp Biopharmaceutical, Inc. (Mapp) investigational products may be made available for use in eligible patients with documented disease or a well-documented high-risk exposure to a pathogen for which Mapp has available material. Mapp investigational products available under expanded access are investigational medicine, and have not been licensed by the U.S. Food and Drug Administration (FDA) or other health authorities. Patients should work closely with their physician to understand the potential benefits and risks of an investigational product prior to use. Physicians seeking expanded access to Mapp investigational products for a patient should submit their request to [email protected].
- Website
-
http://www.mappbio.com
External link for Mapp Biopharmaceutical Inc
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2003
Locations
-
Primary
Get directions
4921 Directors Pl
Suite 100
San Diego, California 92121, US
Employees at Mapp Biopharmaceutical Inc
Updates
-
Results of a collaboration between Mapp, The University of Texas Medical Branch and Uniformed Services University working on a new Nipah monoclonal antibody countermeasure are now published (https://lnkd.in/eZ_ngCQQ). The mAb was superior to m102.4 (the mAb currently used compassionately for Nipah/Hendra exposures), in a non-human primate model. This work was funded by The National Institutes of Health through a CETR grant awarded to Christopher Broder and in collaboration with Tom Geisbert. Moving forward, together with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) Mapp is funded for advancing an extended half-life version of the antibody (MBP1F5) – and Phase 1 testing is expected to begin this year.
-
Check out our new study showing long-term monoclonal antibody prophylaxis against aerosol exposure to Marburg virus. Dafna Abelson led this study together with Robert W. Cross, Ph.D., MPH and Tom Geisbert at The University of Texas Medical Branch. Thanks to the Defense Threat Reduction Agency and Lucy Ward for supporting the work. https://lnkd.in/e-8jFHjq
Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody
academic.oup.com